Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

(19)

(11)

EP 2 233 135 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	10.07.2013 Bulletin 2013/28

(45)	Mention of the grant of the patent:
	27.06.2012 Bulletin 2012/26

(21)	Application number: 09015563.1

(22)	Date of filing: 16.10.2008

(51)

International Patent Classification (IPC):

A61K 31/00^(2006.01)
A61K 31/18^(2006.01)
A61K 31/404^(2006.01)
A61K 31/4704^(2006.01)
A61K 31/36^(2006.01)

A61K 31/138^(2006.01)
A61K 31/222^(2006.01)
A61K 31/4045^(2006.01)
A61K 31/5377^(2006.01)
A61P 35/00^(2006.01)

(54)	Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas Verwendung von Beta-blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA MK RS

(30)

Priority:

19.10.2007 EP 07291273
21.11.2007 US 989507 P

(43)	Date of publication of application:
	29.09.2010 Bulletin 2010/39

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	08838691.7 / 2187878

(73)	Proprietors:
	Université Bordeaux Segalen 33076 Bordeaux Cedex (FR) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR Centre Hospitalier Universitaire de Bordeaux 33404 Talence (FR)

(72)	Inventors:
	Léauté-Labréze, Christine 33185 Le Haillan (FR) Dumas de la Roque, Éric 33140 Villenave d'Ornon (FR) Taieb, Alain 33000 Bordeaux (FR) Thambo, Jean-Benoit 33000 Bordeaux (FR)

(74)	Representative: Novagraaf Technologies
	122 rue Edouard Vaillant 92593 Levallois-Perret Cedex 92593 Levallois-Perret Cedex (FR)

(56)

References cited: :

WO-A-97/40830
WO-A1-2006/122007

WO-A-2006/015830

AH-FAT F G ET AL: "Recurrent visual loss secondary to an iris microhaemangioma [1]" EYE 1994 GB, vol. 8, no. 3, 1994, page 357, XP008089190 ISSN: 0950-222X
GOODFIELD M J ET AL: "The clinical presentation of cutaneous angiolipomata and the response to beta-blockade." CLINICAL AND EXPERIMENTAL DERMATOLOGY MAY 1988, vol. 13, no. 3, May 1988 (1988-05), pages 190-192, XP008089157 ISSN: 0307-6938
BREM H ET AL: "The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis" JOURNAL OF PEDIATRIC SURGERY 1993 US, vol. 28, no. 10, 1993, pages 1253-1257, XP002473031 ISSN: 0022-3468
PAPATHANASSIU, ADONIA E.: "Novel inhibitors of angiogenesis and their mechanism(s) of action" 158 PP. AVAIL.: UMI, ORDER NO. DA9828828 FROM: DISS. ABSTR. INT., B 1998, 59(4), 1454, 1998, XP008089194
LUTGENDORF SUSAN K ET AL: "Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 OCT 2003 LNKD- PUBMED:14555525, vol. 9, no. 12, 1 October 2003 (2003-10-01), pages 4514-4521, XP002590205 ISSN: 1078-0432
THAKER PREMAL H ET AL: "Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma" NATURE MEDICINE, vol. 12, no. 8, August 2006 (2006-08), pages 939-944, XP002590206 ISSN: 1078-8956
RAZON MARIA J ET AL: "Increased apoptosis coincides with onset of involution in infantile hemangioma" MICROCIRCULATION (PHILADELPHIA), vol. 5, no. 2-3, September 1998 (1998-09), pages 189-195, XP002590207 ISSN: 1073-9688
SMITH SALLY K SOMMERS ET AL: "Beta blockade induces apoptosis in cultured capillary endothelial cells" IN VITRO CELLULAR AND DEVELOPMENTAL BIOLOGY ANIMAL, vol. 38, no. 5, May 2002 (2002-05), pages 298-304, XP002590208 ISSN: 1071-2690
BAGHESTANIAN M: "The role of beta-adrenergic blockers as antihypertensive medication in patients with peripheral arterial disease" ZEITSCHRIFT FUR GEFASSMEDIZIN 2006 AT, vol. 3, no. 2, 2006, pages 11-16, XP002590209
LÉAUTÉ-LABRÈZE CHRISTINE ET AL: "Propranolol for severe hemangiomas of infancy." 12 June 2008 (2008-06-12), THE NEW ENGLAND JOURNAL OF MEDICINE 12 JUN 2008, VOL. 358, NR. 24, PAGE(S) 2649 - 2651 , XP002523408 ISSN: 1533-4406 * the whole document *
BONIFAZI E ET AL: "Propranolol in rapidly growing hemangiomas" 2008, EUROPEAN JOURNAL OF PEDIATRIC DERMATOLOGY 2008 IT, VOL. 18, NR. 3, PAGE(S) 185 - 192 , XP008105082 ISSN: 1122-7672 * abstract * * page 185, column 1, paragraph 2 - page 186, column 2, paragraph 2l * * page 186 * * page 192, column 1, paragraph 1 - column 2, paragraph 1 *
CREMER H -J: "Propranolol: A milestone in the treatment of problematic hemangiomas?" October 2008 (2008-10), MONATSSCHRIFT FUR KINDERHEILKUNDE 200810 DE, VOL. 156, NR. 10, PAGE(S) 942 - 943 , XP002523410 ISSN: 0026-9298 * page 942 *
LEAUTE-LABREZE C ET AL: "Efficacy of beta-blockers in infantile capillary haemangiomas: The physiopathological significance and therapeutic consequences" December 2008 (2008-12), ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, VOL. 135, NR. 12, PAGE(S) 860-862 , XP008105076 ISSN: 0151-9638 * page 860 - page 861, column 1, last paragraph *
BLANCHET CATHERINE ET AL: "Management of infantile subglottic hemangioma: acebutolol or propranolol?", INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY AUG 2010 LNKD- PUBMED:20557953, vol. 74, no. 8, August 2010 (2010-08), pages 959-961, ISSN: 1872-8464
POPE ELENA ET AL: "Topical timolol gel for infantile hemangiomas: a pilot study.", ARCHIVES OF DERMATOLOGY MAY 2010 LNKD- PUBMED:20479314, vol. 146, no. 5, May 2010 (2010-05), pages 564-565, ISSN: 1538-3652
AKRAM I ET AL: "Iris microhaemangioma presenting with total hyphaema and elevated intraocular pressure.", EYE (BASINGSTOKE), vol. 17, no. 6, August 2003 (2003-08), pages 784-785, ISSN: 0950-222X
KHAN ZIA A ET AL: "Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice", JOURNAL OF CLINICAL INVESTIGATION, vol. 118, no. 7, July 2008 (2008-07), pages 2592-2599, ISSN: 0021-9738
RITTER MATTHEW R ET AL: "Pathogenesis of infantile haemangioma: new molecular and cellular insights", EXPERT REVIEWS IN MOLECULAR MEDICINE, vol. 9, no. 32, November 2007 (2007-11), ISSN: 1462-3994
SUNDINE MICHAEL J ET AL: "Hemangiomas: an overview.", CLINICAL PEDIATRICS APR 2007 LNKD- PUBMED:17416876, vol. 46, no. 3, April 2007 (2007-04), pages 206-221, ISSN: 0009-9228
FITZGERALD PAUL J: "Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer.", CLINICAL EPIDEMIOLOGY 2010 LNKD- PUBMED:20865096, vol. 2, 2010, pages 1-3, ISSN: 1179-1349
Orfanos Garbe: "Therapie der Hautkrankheiten", 2002, Springer-Verlag, Berlin pages 717-718,
GOODFIELD M J D ET AL: "The clinical presentation of cutaneous angiolipomata and the response to beta-blockade", CLINICAL AND EXPERIMENTAL DERMATOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 13, no. 3, 1 January 1988 (1988-01-01), pages 190-192, XP008089157, ISSN: 0307-6938, DOI: 10.1111/J.1365-2230.1988.TB01968.X


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).